Science
Florida Seeks Drug Prescription Data With Names of Patients and Doctors
Florida’s insurance regulator has demanded an unusually intrusive trove of data on millions of prescription drugs filled in the state last year, including the names of patients taking the medications, their dates of birth and doctors they’ve seen.
The Florida Office of Insurance Regulation in January sought this information from pharmacy benefit managers like UnitedHealth’s Optum Rx and CVS Health’s Caremark, companies that oversee prescription drugs for employers and government programs.
It remained unclear why the state was ordering the submission of so much data. In a letter to one benefit manager reviewed by The New York Times, the regulator said the state required the data to review whether the benefit managers, known as P.B.M.s, were compliant with a 2023 state law aimed at lowering drug prices and reining in the managers.
But the demand is sparking concerns about government overreach and patient privacy.
“You don’t need such granular patient information for purposes of oversight,” said Sharona Hoffman, a health law and privacy expert at Case Western Reserve University. She added: “You have to worry: Is the government actually trying to get information about reproductive care or transgender care or mental health care?”
Florida’s six-week abortion ban, enacted by Gov. Ron DeSantis, a Republican, and the state’s Republican-dominated legislature, requires that doctors who prescribe abortion pills dispense them in person, not through the mail. Another Florida law banned transgender transition care for minors and made it harder for adults to seek such care. Last year, a judge struck down key parts of that law, though it is still being enforced while the legal fight makes its way through the courts.
The data requested by the state could, in theory, be used to determine whether physicians are complying with those laws.
It was also unclear whether any of the benefit managers had complied and turned over the information to the state.
Some benefit managers and the employers that hire them to handle prescription drug benefits for their workers have also criticized the state’s demand.
A group of large employers, the American Benefits Council, is asking the Florida regulator to withdraw its order to turn over the information. In a letter to the state, the council’s lawyers wrote that the “demand impermissibly violates the health privacy and security of millions of Floridians,” and that the state had not clearly outlined its authority or reasons for the action.
“We have a duty to employees and their data,” Katy Johnson, the president of the council, said in an interview.
Shiloh Elliott, a spokeswoman for Florida’s insurance regulator, said that objections to the state’s data request “are clearly from those who do not want to be regulated or have any oversight in their industry.” She said the office “will continue to request data in the best interest to protect consumers.”
Rosa Novo, the administrative benefits director for Miami-Dade County Public Schools, which provides health coverage to about 45,000 people, said in an interview that while she appreciated the state’s efforts to address drug prices, it was unclear why it would need this level of detailed information about patients and their medications.
“My doctor is the only one who should know that,” Ms. Novo said.
Federal privacy law allows benefit managers to hand over limited data about individual patients in certain circumstances, such as when regulators are conducting an audit. But, according to experts, Florida’s data request could violate the law because it is so broad and may go beyond what the regulator needs to conduct its review.
Experts said that another concern with Florida’s request is that when sensitive patient data is in multiple hands, it raises the risk of a breach in which the information may be stolen.
Ms. Elliott, the spokeswoman for the regulator, said those concerns “should be addressed to the actual health care insurance companies that have had countless data breaches exposing millions of Americans’ sensitive information.”
Florida’s data order was first reported by Bloomberg.
Like other states, Florida already has access to some of the data it is seeking, such as detailed information about prescriptions that are paid through Medicaid. But that data is generally strictly walled off, accessible only to staff members whose jobs require it.
Benefit managers often field requests from government regulators asking for slices of data to conduct audits or investigations. Such requests typically ask benefit managers to strip out patient names, and other identifying details, or ask for a small sample of patient claims.
By comparison, Florida’s data request was “pretty expansive and unprecedented,” said Joseph Shields, the president of a group of smaller benefit managers, Transparency-Rx.
Florida sought data not only on Florida residents, but also on patients who may have filled a prescription while visiting the state. Its request included patients covered through the federal Medicare program and commercial plans through employers that are regulated under federal law rather than state law, according to the regulator’s letter to one benefit manager reviewed by The Times.
The Prescription Drug Reform Act, the Florida law the regulator used to justify the data request, imposed new reporting requirements on the benefit managers but said nothing about a mandate requiring them to turn over such detailed patient information. Benefit managers have fiercely fought efforts to scrutinize their business practices.
Patricia Mazzei contributed reporting from Florida.
new video loaded: Pentagon Releases U.F.O. Files
By Jorge Mitssunaga
May 8, 2026
President Trump has signed off on a plan to fire Dr. Marty Makary, commissioner of the Food and Drug Administration, after a series of clashes over vaping, oversight of the abortion pill and a series of new drug application denials that rattled biotech companies, according to a person briefed on the matter, who was not authorized to discuss it publicly.
Dr. Makary had a high profile for an F.D.A. commissioner, appearing frequently on television and podcasts to sell the work he was doing at the agency on improving the food supply, speeding up some drug approvals and trying to restore agency morale after thousands of staff members left.
He tried to walk the tightrope between the business-friendly Make America Great Again movement, pledging to get rid of regulations that slow down innovation and to attract more drug trials to the United States. He was an ally of Health Secretary Robert F. Kennedy Jr.’s Make American Healthy Again supporters, voicing the skepticism of the pharmaceutical industry and authorizing natural food dyes.
Ultimately, Dr. Makary’s efforts were not enough to overcome the grievances of a growing band of enemies focused on selling tobacco, opposing abortion and seeing biotech therapies authorized.
Mr. Trump’s decision to dismiss him was first reported by The Wall Street Journal.
The decision could still change, given Mr. Trump’s propensity to change his mind Dr. Makary has also proven persuasive with Mr. Trump in beating back previous efforts to oust him.
Leaving the White House Friday evening, Mr. Trump dismissed the idea that Dr. Makary would be fired.
“I’ve been reading about it, but I know nothing about it,” he said.
The White House has pressured Dr. Makary for months to authorize flavored e-cigarettes, according to a person close to the conversations. The approvals were a top wish of major tobacco companies that have been top donors to Mr. Trump. In March, the F.D.A. issued a memo saying that it would only authorize e-cigarettes in flavors such as mint, tea and spices. The memo said the fruit and candy flavors would be unlikely to pass muster, given their appeal to young people.
Pressure continued, though, and on Tuesday the F.D.A. authorized blueberry and mango flavored e-cigarettes by Glas, a small company based in Los Angeles.
Abortion foes including Susan B. Anthony Pro-Life America have continued to turn up the heat on Dr. Makary, reiterating their call for his firing on Thursday. The group’s leaders and others view Dr. Makary as dragging his feet on a safety review of the abortion pill mifepristone, which they viewed as a way to highlight what they believe are dangers of the drug. Former Vice President Mike Pence, who also opposes abortion rights, amplified criticism of Dr. Makary on social media as well.
The administration has been under pressure from conservatives to tighten regulations on the prescribing and dispensing of mifepristone. The Supreme Court is reviewing a federal appeals court ruling that temporarily blocked abortion providers from prescribing the drug through telemedicine and sending it to patients by mail.
Biotech companies and their investors have also raised alarms with the White House about agency decisions to reject a series of treatments for rare diseases. The F.D.A. typically turns down about 20 percent of the applications it receives for drug approvals from companies.
Dr. Makary has been aggressive in defending the decisions, which he said came from career scientists who found the medications ineffective.
Dr. Makary also had to contend with a health secretary who seemed to view the F.D.A. as an avenue for getting his favored products authorized, exemplified by Mr. Kennedy’s social media post saying that the agency would end its “war on” stem cell treatments, peptides and raw milk. Mr. Kennedy pushed the F.D.A. to reverse a 2023 ban and allow the use of a number of peptides, unproven compounds purported to offer anti-aging or muscle-recovery benefits.
Before leading the F.D.A., Dr. Makary was a cancer surgeon and health policy researcher at Johns Hopkins University School of Medicine. He was also the author of several books about the health care system.
Some of Dr. Makary’s more popular moves included encouraging broader use of hormone replacement products for women and lifting the F.D.A.’s warnings on them. He helped speed some promising drugs to market, including a pancreatic cancer therapy and the pill form of the popular GLP-1 weight loss drugs.
Some California residents were among the 147 passengers and staff aboard a luxury cruise ship stricken by a suspected outbreak of hantavirus that has left three people dead and several others severely ill, officials confirmed Thursday.
California public health officials say they are monitoring the situation after being notified by the U.S. Centers for Disease Control and Prevention that some state residents were passengers on the MV Hondius. The precise status of those individuals, however, remains murky.
Hantavirus is a rare but deadly disease that attacks the lungs and is typically contracted by humans through inhalation of particles contaminated with the urine, feces or saliva of a wild rodent.
However, Dr. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, confirmed Thursday that the Andes virus — a form of hantavirus that can spread from person to person — was involved in the outbreak.
Here’s what we know:
The MV Hondius cruise ship anchored at a port in Praia, Cape Verde, on Wednesday.
(Misper Apawu / Associated Press)
As its name suggests, the Andes virus is typically found in South America. The Dutch-flagged MV Hondius was on a 46-day journey that traveled from Antarctica with stops in Argentina.
In the case of human-to-human transmission, a person would first be infected by a wild rodent’s contaminated particles and then pass the infection to someone else, said Dr. Gaby Frank, director of the Johns Hopkins Special Pathogens Center.
“In previous outbreaks of Andes virus, transmission between people has been associated with close and prolonged contact, particularly among household members, intimate partners and people providing medical care,” Ghebreyesus said. “That appears to be the case in the current situation.”
None of the remaining passengers or crew members on the ship are symptomatic, he said.
The ship was not permitted to allow passengers to disembark at its original destination, Cape Verde, and is sailing for Spain’s Canary Islands.
“I want to be unequivocal here: This is not SARS-CoV-2. This is not the start of a COVID pandemic. This is an outbreak that we see on a ship. There’s a confined area,” Dr. Maria Van Kerkhove, who leads the WHO’s epidemic and pandemic management, said at a briefing. “This is not the same situation we were in six years ago. It doesn’t spread the same way like coronaviruses do.”
California passengers on the cruise
On April 1, 114 guests boarded the cruise ship in Ushuaia, Argentina. Twenty-three days later, 30 passengers — including six people from the United States — disembarked on a stop in St. Helena, a remote island about 1,100 miles off the coast of Africa, according to the cruise operator Oceanwide Expeditions.
Public health agencies in California, Georgia and Arizona were notified by the CDC that some of their residents were among the passengers on the cruise. It’s unclear whether these individuals disembarked on April 24, however.
The CDC is assisting local health authorities with monitoring California residents who were aboard the cruise, according to a statement by the California Department of Public Health on Friday.
As of Friday, one passenger has returned to their California residence and is in contact with local public health officials, and at least one other remains aboard the ship, according to the state agency.
“We understand that news of an unusual outbreak can be concerning,” said Dr. Erica Pan, director of the California Department of Public Health. “Unlike influenza and COVID-19, years of experience in South America have shown that this Andes hantavirus rarely spreads between people.”
Officials said the current public health protocol is to do daily symptom monitoring and reporting.
“As there are no known cases of Andes hantavirus infection from people without symptoms, and any spread has usually been limited to people with prolonged close contact with an ill person with this virus, the risk to the general public in California is extremely low,” the agency said in a statement.
In a statement earlier this week, the CDC also said that the risk to the American public “is extremely low” at this time.
“We urge all Americans aboard the ship to follow the guidance of health officials as we work to bring you home safely,” the agency said.
The others who exited the ship on April 24 were individuals from Canada, Denmark, Germany, the Netherlands, New Zealand, Switzerland, Sweden, Singapore, St. Kitts and Nevis, Turkey and the United Kingdom.
Of the remaining passengers still aboard the ship headed for Spain’s Canary Islands, California Department of Public Health said none were ill as of Friday.
How many people have been infected?
The number of lab-confirmed hantavirus cases has risen to five, according to the WHO. There are three additional suspected cases.
A timeline of reported cases of hantavirus aboard the cruise ship can be found here.
The WHO is monitoring reports of other people with symptoms “who may have had contact with one of the passengers. In each case, we are in close contact with the relevant authorities,” Tedros said.
The first passenger to have been infected, a Dutchman, became sick aboard the cruise ship on April 6 and died on April 11.
No samples were taken, because his symptoms were similar to other respiratory diseases. His widow left the ship with his body on April 24 during the scheduled stop at St. Helena.
“She deteriorated during a flight to Johannesburg on the 25th of April and died the next day,” Tedros said.
Before boarding the cruise ship, the Dutch couple had traveled through Argentina, Chile and Uruguay on a bird-watching trip, “which included visits to sites where the species of rat that is known to carry Andes virus was present,” Tedros said.
After leaving the ship, the woman was briefly aboard a KLM aircraft in Johannesburg bound for Amsterdam but was barred from the flight due to her medical condition, the airline said in a statement.
Dutch news outlets reported that a flight attendant on a KLM airplane — who briefly had contact with the widow — started feeling sick and had mild symptoms and was in isolation at a hospital in Amsterdam.
The flight attendant has since tested negative for the Andes virus, Dr. Jeremy Faust, an emergency medicine physician, wrote on his Substack blog, Inside Medicine, citing a text message sent to him by Tedros.
“It is still possible that the flight attendant contracted the Andes virus. However, given our understanding of the virus, this information means that the flight attendant’s symptoms are not caused by the Andes hantavirus, but by some other medical illness,” Faust wrote.
More cases may be reported, because the incubation period — the time it takes between exposure to the virus and the onset of illness — for the Andes strain of the hantavirus is up to six weeks.
What we know about hantavirus
There are roughly 50 identified species of hantavirus. The virus that’s found in the Americas tends to cause a cardiopulmonary syndrome, a condition that affects the heart and the lungs, according to Frank.
There have been 890 laboratory-confirmed cases of hantavirus disease reported in the U.S. since surveillance began in 1993, according to the most recent data from the CDC.
From 1980 to 2025, 99 California residents have been diagnosed with a hantavirus infection, according to the California Department of Public Health.
CDC officials said 38% of people who develop respiratory symptoms may die from the disease.
Still, the data suggest that contracting hantavirus is rare, said Dr. Afif El-Hasan, member of the American Lung Assn.’s national board of directors.
There is no vaccine or specific antiviral medicine for hantavirius.
Intensive-care treatment may include intubation and oxygen therapy, fluid replacement and use of medications to lower blood pressure, according to the American Lung Assn.
The signs of hantavirus
Early symptoms of hantavirus are similar to the flu and include fatigue, fever and muscle aches, according to the CDC. Symptoms start to develop within one to eight weeks after contact with an infected rodent.
Half of those who contract the virus also experience headaches, dizziness, chills, nausea, vomiting, diarrhea and abdominal pain.
Four to 10 days after the initial phase of the illness, another round of symptoms can develop, which include coughing, shortness of breath and possible tightness in the chest as the lungs fill with fluid.
Even though contracting hantavirus in the U.S. continues to be a rare event, El-Hasan said, people should take these initial symptoms seriously and promptly seek medical care.
How to protect yourself
Hantavirus cases can occur year-round, but the peak seasons in the United States are the spring and summer, which coincide with the reproductive seasons for deer mice.
To lessen your risk of infection, keep wild rodents out of your home and other enclosed spaces by sealing any holes and placing snap traps.
If you find evidence of mice, wear personal protective equipment and disinfect the area. When you’re done, put everything, including cleaning materials, in a bag and toss it in your trash bin.
-
North Dakota37 seconds agoFederal judge agrees to toss $28M judgment related to Dakota Access Pipeline protests
-
Ohio7 minutes ago8th Annual Trumbull County Special Olympics Invitational held in Girard
-
Oklahoma13 minutes agoKendall Wells Falls Behind in Home Run Race as Oklahoma Waits for Selection Sunday
-
Oregon19 minutes ago4.9 magnitude earthquake strikes off Northern California coast near Oregon border
-
Pennsylvania25 minutes agoPennsylvania Medical Marijuana And Hemp Regulation Bill Sets The State Up For Broader Recreational Legalization, GOP Senator Says – Marijuana Moment
-
Rhode Island31 minutes agoProposed tax hike would hurt small businesses and our communities | Opinion
-
South-Carolina37 minutes ago11 Unforgettable Small Towns to Visit in South Carolina
-
South Dakota43 minutes agoHuman trafficking survivor advocate to speak at Rapid City church event